Cargando…

Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?

Detalles Bibliográficos
Autores principales:	Balzarotti, Monica, Santoro, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475490/ https://www.ncbi.nlm.nih.gov/pubmed/32953835 http://dx.doi.org/10.21037/atm.2020.04.06

Ejemplares similares

Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020)

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
por: Tomassetti, Sarah, et al.
Publicado: (2019)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Targeting primary mediastinal B-cell lymphoma
por: Wagner, Simon D.
Publicado: (2014)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma
por: Bojanini, Leyla, et al.
Publicado: (2023)

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
por: Lucchini, Elisa, et al.
Publicado: (2021)

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022)

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
por: Guo, Yuelu, et al.
Publicado: (2023)

Virus Taxonomy: One Step Forward, Two Steps Back
por: Eberhard, Mark
Publicado: (2004)

Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
por: Castagna, Luca, et al.
Publicado: (2015)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Mediastinal cryptococcosis masquerading as therapy-refractory lymphoma
por: Wong, Matthew, et al.
Publicado: (2010)

HPV Vaccination in Males: Another Step Forward
por: Cai, Tommaso
Publicado: (2015)

Clinical Islet Xenotransplantation: A Step Forward
por: Ekser, Burcin, et al.
Publicado: (2016)

Serious games for health: three steps forwards
por: Drummond, David, et al.
Publicado: (2017)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

A step forward understanding HIV-1 diversity
por: Smyth, Redmond P., et al.
Publicado: (2016)

Inclusion of Radiopharmaceuticals in the Indian Pharmacopeia: A Step Forward
por: Meher, Bikash Ranjan
Publicado: (2020)

Checkpoint inhibitors and myeloma: promises, deadlocks and new directions
por: Bertamini, Luca, et al.
Publicado: (2020)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Is there a role for allogeneic hematopoietic stem cell transplantation for refractory follicular lymphoma?
por: Yang, Yang, et al.
Publicado: (2022)

Thyroid research: stepping forward
por: Vaidya, Bijay, et al.
Publicado: (2016)

Stepping Down, Looking Forward
por: Chabner, Bruce A
Publicado: (2022)

Welcome - First Step Forward
por: Ahuja, Maninder, et al.
Publicado: (2022)

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

iPSC-Based Cell Therapy: An Important Step Forward
por: Rao, Mahendra
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_so67kbod3h7f8tm7js9v58t06n